1.
Increasing burden of liver disease in patients with HIV infection
by Joshi, Deepak, MRCP
The Lancet (British edition), 2011, Vol.377 (9772), p.1198-1209
2.
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial
by McCormack, Sheena, Prof
The Lancet (British edition), 2016, Vol.387 (10013), p.53-60
3.
Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM
by Martin, Thomas C.S
AIDS (London), 2013-10-23, Vol.27 (16), p.2551-2557
4.
Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome
by WALSH, John C
AIDS (London), 2002, Vol.16 (2), p.269-277
5.
Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observ...
by Phillips, Andrew N, Prof
The Lancet (British edition), 2007, Vol.370 (9603), p.1923-1928
6.
A trial of caspofungin salvage treatment in PCP pneumonia
by Armstrong-James, Darius
Thorax, 2011-06, Vol.66 (6), p.537-538
7.
1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals
by Gazzard, Brian
The Lancet (British edition), 1998-07-25, Vol.352 (9124), p.314-316
8.
Antiretroviral therapy for HIV: medical miracles do happen
by Gazzard, Brian
The Lancet (British edition), 2005, Vol.366 (9483), p.346-347
9.
Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors
by MOYLE, Graeme J
AIDS (London), 2002, Vol.16 (10), p.1341-1349
10.
Risk of HIV transmission in discordant couples
by Garnett, Geoffrey P
The Lancet (British edition), 2008, Vol.372 (9635), p.270-271
11.
Maintaining cost-effective access to antiretroviral drug therapy through a collaborative approach to drug procurement, consensus treatment guidelines and regular audit: the experie...
by Foreman, Claire
Sexually transmitted infections, 2012-03, Vol.88 (2), p.112-115
12.
Reduced TH1/TH17 CD4 T-cell numbers are associated with impaired purified protein derivative―specific cytokine responses in patients with HIV-1 infection
by CLARK, Sally
Journal of allergy and clinical immunology, 2011, Vol.128 (4), p.838-846
13.
Switch from inhibitory to activating NKG2 receptor expression in HIV-1 infection : lack of reversion with highly active antiretroviral therapy
by MELA, Christopher M
AIDS (London), 2005, Vol.19 (16), p.1761-1769
14.
An open-label assessment of TMC 125: a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance
by GAZZARD, Brian G
AIDS (London), 2003, Vol.17 (18), p.F49-F54
15.
Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy
by MOYLE, Graeme J
AIDS (London), 2001, Vol.15 (12), p.1503-1508
16.
Short Communication: NKG2C+ NK Cells Contribute to Increases in CD16+CD56− Cells in HIV Type 1+ Individuals with High Plasma Viral Load
by Gregson, John N.S
AIDS research and human retroviruses, 2013-01-01, Vol.29 (1), p.84-88
17.
Reduced T(H)1/T(H)17 CD4 T-cell numbers are associated with impaired purified protein derivative-specific cytokine responses in patients with HIV-1 infection
by Clark, Sally
Journal of allergy and clinical immunology, 2011-10, Vol.128 (4), p.838-846.e5
18.
Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma
by POWLES, Tom
AIDS (London), 2002, Vol.16 (4), p.531-536
19.
Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen
by BOFFITO, Marta
AIDS (London), 2004, Vol.18 (9), p.1291-1297
20.
Data linkage reduces loss to follow-up in an observational HIV cohort study
by Hill, Teresa
Journal of clinical epidemiology, 2010, Vol.63 (10), p.1101-1109
